Per Norlén, MD, PhD, has extensive experience in the life science industry overall and particularly in the development of cancer drugs. With over 20 years of experience in various international leadership positions within the pharmaceutical industry, spanning both Big Pharma and the biotechnology sector, Per most recently served as the CEO of the Danish biotechnology company Evaxion Biotech A/S, listed on Nasdaq in New York. From 2015 to 2021, Per Norlén was the CEO of Alligator Bioscience AB, a cancer research company listed on Nasdaq Stockholm in 2016, where he also served as Chief Medical Officer and Chief Development Officer. He has also worked in drug development at AstraZeneca and at Lund University Hospital.
Per graduated as a medical doctor from Lund University, earned a PhD in preclinical pharmacology, and subsequently became an associate professor in clinical pharmacology. He is also a board-certified specialist in clinical pharmacology with extensive experience in the clinical development of cancer drugs. Per also has years of experience in business development and has been responsible for several major collaboration agreements between biotechnology companies and Big Pharma.